Company news

Larimar Therapeutics, Inc. news in 2023

Larimar Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results

November 13, 2023

Larimar Therapeutics Appoints Dr. Jeffery W. Sherman to its Board of Directors

October 2, 2023

Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results

August 9, 2023

Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601’s Phase 2 Friedreich's Ataxia Trial and to Initiate Open Label Extension Trial

July 24, 2023

Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer

July 16, 2023

Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trial’s 25 mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreich’s Ataxia and First Quarter 2023 Financial Results

May 14, 2023

Larimar Therapeutics Reports Fourth Quarter and Full Year 2022 Operating and Financial Results

March 13, 2023

Larimar Therapeutics Appoints Dr. Gopi Shankar as Chief Development Officer

February 6, 2023

Decks in 2023